Get the Stockscreener App
6.25
3.99%
0.24
Wave Life Sciences Ltd stock is traded at $6.25, with a volume of 957.74K.
It is up +3.99% in the last 24 hours and down -22.84% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$6.01
Open:
$6.09
24h Volume:
957.74K
Relative Volume:
0.66
Market Cap:
$963.31M
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-5.6306
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
+5.04%
1M Performance:
-22.84%
6M Performance:
-59.07%
1Y Performance:
+1.13%
1-Day Range:
$5.99
$6.33
1-Week Range:
$5.92
$6.33
52-Week Range:
$4.25
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
6.25 | 915.56M | 53.61M | -142.52M | -141.83M | -1.11 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Risks Still Elevated At These Prices As Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Dive 26% - simplywall.st
Nuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference | WVE Stock News - GuruFocus
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Wave Life Sciences CEO Reveals Next-Gen RNA Medicine Plans at Major Healthcare Conference - Stock Titan
Wave Life Sciences Announces Appointment Of Dr. Christopher Wright As Chief Medical Officer - marketscreener.com
Wave Life Sciences (WVE) Appoints New Chief Medical Officer | WV - GuruFocus
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer - GlobeNewswire
Wave Life Sciences (WVE) Appoints New Chief Medical Officer | WVE Stock News - GuruFocus
Harvard Professor to Chief Medical Officer: Wave Life Sciences Taps RNA Expert Behind Breakthrough FDA Approvals - Stock Titan
WaVe Life Sciences’ SWOT analysis: RNA editing pioneer faces fierce competition - Investing.com Nigeria
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $648,000 Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Bank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Deutsche Bank AG Purchases 25,756 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now? - MSN
BNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of “Buy” by Analysts - Defense World
Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust Corp - Defense World
(WVE) On The My Stocks Page - news.stocktradersdaily.com
FY2025 Earnings Estimate for WVE Issued By Cantor Fitzgerald - Defense World
Raymond James Financial Inc. Takes $157,000 Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
H.C. Wainwright maintains $22 target on WAVE Life Sciences stock - Investing.com Australia
H.C. Wainwright maintains $22 target on WAVE Life Sciences stock By Investing.com - Investing.com India
Wave Life Sciences (NASDAQ:WVE) Stock Rating Lowered by StockNews.com - Defense World
Wave Life Sciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Despite shrinking by US$215m in the past week, Wave Life Sciences (NASDAQ:WVE) shareholders are still up 407% over 3 years - simplywall.st
RBC Cuts Price Target on Wave Life Sciences to $9 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Wave Life Sciences Reports Q1 2025 Financials and Progress - TipRanks
Wave Life Sciences: Q1 Earnings Snapshot - New Haven Register
WAVE Life Sciences Ltd (WVE) Q1 2025 Earnings Call Highlights: Clinical Advancements and ... - Yahoo Finance
Wave Life Sciences (NASDAQ:WVE) Shares Gap Down Following Weak Earnings - Defense World
Decoding WAVE Life Sciences Ltd (WVE): A Strategic SWOT Insight - GuruFocus
Transcript : Wave Life Sciences Ltd., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Wave Life Sciences Ltd earnings missed by $0.04, revenue fell short of estimates - Investing.com Nigeria
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update | WVE Stock News - GuruFocus
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates - Yahoo
Wave Life Sciences (WVE) Misses Revenue Estimates, Advances Clinical Trials | WVE Stock News - GuruFocus
Wave Life Sciences Reports Q1 2025 Financial Results - TipRanks
WAVE LIFE SCIENCES Earnings Results: $WVE Reports Quarterly Earnings - Nasdaq
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (WVE) Wave Life Sciences Reports Q1 Revenue $9.2M, vs. FactSet Est of $11.9M - marketscreener.com
WAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Kno - GuruFocus
WAVE Life Sciences Earnings Preview - Nasdaq
WAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):